Kintor Pharmaceutical Limited
KNTPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $5,000 | $0 | $0 | $34,231 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $9,730 | $42,229 | $2,737 | $0 |
| Gross Profit | -$4,730 | -$42,229 | -$2,737 | $34,231 |
| % Margin | -94.6% | – | – | 100% |
| R&D Expenses | $78,143 | $938,907 | $827,974 | $768 |
| G&A Expenses | $61,825 | $27,638 | $43,468 | $44,993 |
| SG&A Expenses | $88,383 | $34,622 | $63,794 | $59,691 |
| Sales & Mktg Exp. | $26,558 | $6,984 | $20,326 | $14,698 |
| Other Operating Expenses | -$26,688 | $43,465 | -$748,541 | $813,373 |
| Operating Expenses | $139,838 | $1,016,994 | $143,227 | $873,832 |
| Operating Income | -$144,568 | -$152,390 | -$944,529 | -$839,601 |
| % Margin | -2,891.4% | – | – | -2,452.8% |
| Other Income/Exp. Net | -$10,706 | $1,175 | -$8,755 | -$2,494 |
| Pre-Tax Income | -$155,274 | -$151,215 | -$953,284 | -$842,095 |
| Tax Expense | $18 | -$8,041 | $1,085 | $0 |
| Net Income | -$155,292 | -$1,060,820 | -$954,369 | -$842,095 |
| % Margin | -3,105.8% | – | – | -2,460% |
| EPS | -0.36 | -2.47 | -2.53 | -2.36 |
| % Growth | 85.4% | 2.4% | -7.2% | – |
| EPS Diluted | -0.36 | -2.47 | -2.53 | -2.36 |
| Weighted Avg Shares Out | 430,724 | 429,069 | 376,566 | 356 |
| Weighted Avg Shares Out Dil | 430,724 | 429,069 | 376,566 | 356 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4,209 | $13,077 | $6,882 | $12,049 |
| Interest Expense | $9,277 | $9,690 | $8,187 | $2,494 |
| Depreciation & Amortization | $17,627 | $13,854 | $12,678 | $10,510 |
| EBITDA | -$128,370 | -$1,055,821 | -$956,446 | -$827,967 |
| % Margin | -2,567.4% | – | – | -2,418.8% |